DRI Healthcare Trust (TSE:DHT.UN) Price Target Raised to C$20.00 at CIBC

DRI Healthcare Trust (TSE:DHT.UN) had its price target increased by CIBC from C$19.50 to C$20.00 in a research note issued to investors on Wednesday, BayStreet.CA reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on DHT.UN. Raymond James upgraded shares of DRI Healthcare Trust from an outperform rating to a strong-buy rating and upped their price target for the stock from C$22.00 to C$24.00 in a research note on Friday, March 1st. National Bankshares raised their target price on shares of DRI Healthcare Trust from C$22.00 to C$23.50 and gave the company an outperform rating in a research note on Friday, March 1st. Stifel Nicolaus raised their target price on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company a buy rating in a research note on Friday, March 1st. Finally, Scotiabank raised their target price on shares of DRI Healthcare Trust from C$22.00 to C$24.00 and gave the company an outperform rating in a research note on Friday, February 2nd. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, DRI Healthcare Trust has an average rating of Buy and an average target price of C$21.50.

DRI Healthcare Trust Stock Performance

Shares of DRI Healthcare Trust stock opened at C$16.22 on Wednesday. The stock has a fifty day moving average price of C$16.26. DRI Healthcare Trust has a 12-month low of C$8.85 and a 12-month high of C$17.43.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.